Sign up Australia
Proactive Investors - Run By Investors For Investors

Proteomics International Laboratories set to ship first commercial batch of its immunoassay kit

PromarkerD is the world's first commercial test for predicting the onset of diabetic kidney disease.
The new immunoassay kit can be used by pathology laboratories

Proteomics International Laboratories Ltd (ASX:PIQ) will ship the first commercial batch of its new PromarkerD immunoassay kit on November 20, 2018 following positive performance verification results.

This follows the production of key antibody reagents in Puerto Rico, and manufacture of the kit in California, both instigated in partnership with licence partner Omics Global Solutions.

Positive verification results on the PromarkerD immunoassay kit will be presented today at the 18th Annual Diabetes Technology Meeting in North Bethesda, US.

The PromarkerD kit will be used to target new commercialisation deals in Japan and India, opening the door to further commercialisation discussions around the world.

Proteomics’ PromarkerD mass spectrometry Laboratory Developed Test (LDT) has already been licensed in USA, Mexico and Spain.

The LDT permits fast adoption of a new test in advanced markets and is being used to build market demand prior to the wider release of the PromarkerD kit.

The world-first test for predicting the onset of diabetic kidney disease was recently licensed to PHDx (Austin, Texas) for launch in the US.

It is also due to launch in Mexico and Spain in the New Year.

Proteomics managing director Dr Richard Lipscombe said: “Diabetes and diabetes-associated diseases are a major global health problem that put an ever-increasing burden on the health sector.

“PromarkerD could save the US healthcare system up to US$100 billion per year in direct costs associated with treating end-stage kidney disease."

“We are delighted that the results of the PromarkerD Kit have been accepted for presentation at the 18th Annual Diabetes Technology Meeting.

“This shows the power of the Promarker TM technology platform and what Proteomics International is doing in the field of predictive testing for global diseases”.

View full PIQ profile View Profile

Proteomics International Laboratories Ltd Timeline

Related Articles

September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use